4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001209191-20-064659
Chief Executive Officer sold 4,999 shares at $25.00 ($124,975)
- Chief Executive Officer acquired 4,999 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Ballal Rahul D. · Chief Executive Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2020-12-17 | Exercise or conversion : show line 1 in the form | +4,999 | $3.15 | $15,747 | 4,999 | D |
| 2020-12-17 | Sale : show line 2 in the form | −4,999 | $25.00 | $124,975 | 0 | D |
| Open-market sales · 4,999 sh · avg $25.00 · $124,975 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2020-12-17 | Exercise or conversion : show line 3 in the form Stock Option (Right to Buy) | −4,999 | 263,999 | D |
Loading xslF345X03/doc4.xml…